S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:HSKA

Heska Competitors

$171.68
+4.80 (+2.88 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$165.60
Now: $171.68
$172.05
50-Day Range
$160.33
MA: $182.18
$207.30
52-Week Range
$50.00
Now: $171.68
$217.17
Volume187,309 shs
Average Volume91,658 shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Competitors

Heska (NASDAQ:HSKA) Vs. QDEL, NEOG, NTLA, RIOT, MYGN, and LNTH

Should you be buying HSKA stock or one of its competitors? Companies in the industry of "diagnostic substances" are considered alternatives and competitors to Heska, including Quidel (QDEL), Neogen (NEOG), Intellia Therapeutics (NTLA), Riot Blockchain (RIOT), Myriad Genetics (MYGN), and Lantheus (LNTH).

Heska (NASDAQ:HSKA) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares Heska and Quidel's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60
Quidel$534.89 million11.97$72.92 million$2.7355.42

Quidel has higher revenue and earnings than Heska. Quidel is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Heska and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heska01402.80
Quidel11302.40

Heska currently has a consensus price target of $185.80, indicating a potential upside of 8.22%. Quidel has a consensus price target of $245.60, indicating a potential upside of 62.33%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than Heska.

Profitability

This table compares Heska and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heska-11.15%-2.29%-1.64%
Quidel36.91%63.31%40.55%

Institutional & Insider Ownership

96.1% of Heska shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 11.7% of Heska shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Summary

Quidel beats Heska on 9 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and Heska (NASDAQ:HSKA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Risk & Volatility

Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neogen and Heska's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million10.15$59.47 million$1.1370.58
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60

Neogen has higher revenue and earnings than Heska. Neogen is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neogen and Heska's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
Heska-11.15%-2.29%-1.64%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Neogen and Heska, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
Heska01402.80

Neogen currently has a consensus target price of $81.50, indicating a potential upside of 2.19%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Heska's stronger consensus rating and higher probable upside, analysts clearly believe Heska is more favorable than Neogen.

Insider & Institutional Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 0.9% of Neogen shares are owned by insiders. Comparatively, 11.7% of Heska shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Heska (NASDAQ:HSKA) and Intellia Therapeutics (NASDAQ:NTLA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Profitability

This table compares Heska and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heska-11.15%-2.29%-1.64%
Intellia Therapeutics-193.01%-40.14%-30.11%

Volatility and Risk

Heska has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Earnings & Valuation

This table compares Heska and Intellia Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55

Heska has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Heska and Intellia Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heska01402.80
Intellia Therapeutics051002.67

Heska currently has a consensus price target of $185.80, suggesting a potential upside of 8.22%. Intellia Therapeutics has a consensus price target of $56.6154, suggesting a potential upside of 9.28%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Heska.

Institutional & Insider Ownership

96.1% of Heska shares are held by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are held by institutional investors. 11.7% of Heska shares are held by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Heska beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Heska (NASDAQ:HSKA) and Riot Blockchain (NASDAQ:RIOT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Volatility & Risk

Heska has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Riot Blockchain has a beta of 4.56, suggesting that its stock price is 356% more volatile than the S&P 500.

Insider and Institutional Ownership

96.1% of Heska shares are owned by institutional investors. Comparatively, 9.0% of Riot Blockchain shares are owned by institutional investors. 11.7% of Heska shares are owned by insiders. Comparatively, 3.5% of Riot Blockchain shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Heska and Riot Blockchain's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heska-11.15%-2.29%-1.64%
Riot Blockchain-250.06%-51.38%-47.50%

Analyst Recommendations

This is a summary of recent recommendations for Heska and Riot Blockchain, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heska01402.80
Riot Blockchain00103.00

Heska currently has a consensus target price of $185.80, suggesting a potential upside of 8.22%. Riot Blockchain has a consensus target price of $28.00, suggesting a potential downside of 30.52%. Given Heska's higher possible upside, equities research analysts plainly believe Heska is more favorable than Riot Blockchain.

Valuation and Earnings

This table compares Heska and Riot Blockchain's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60
Riot Blockchain$6.84 million397.87$-20,040,000.00($0.73)-55.21

Heska has higher revenue and earnings than Riot Blockchain. Riot Blockchain is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Summary

Heska beats Riot Blockchain on 10 of the 14 factors compared between the two stocks.

Myriad Genetics (NASDAQ:MYGN) and Heska (NASDAQ:HSKA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Insider & Institutional Ownership

96.7% of Myriad Genetics shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 2.8% of Myriad Genetics shares are owned by company insiders. Comparatively, 11.7% of Heska shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Myriad Genetics and Heska, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myriad Genetics33001.50
Heska01402.80

Myriad Genetics currently has a consensus price target of $17.20, suggesting a potential downside of 38.22%. Heska has a consensus price target of $185.80, suggesting a potential upside of 8.22%. Given Heska's stronger consensus rating and higher possible upside, analysts plainly believe Heska is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares Myriad Genetics and Heska's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$638.60 million3.28$-199,500,000.00($0.35)-79.54
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60

Heska has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Myriad Genetics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Profitability

This table compares Myriad Genetics and Heska's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myriad Genetics-32.49%-4.07%-2.68%
Heska-11.15%-2.29%-1.64%

Summary

Heska beats Myriad Genetics on 10 of the 14 factors compared between the two stocks.

Lantheus (NASDAQ:LNTH) and Heska (NASDAQ:HSKA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Volatility & Risk

Lantheus has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares Lantheus and Heska's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lantheus0.12%11.05%5.43%
Heska-11.15%-2.29%-1.64%

Earnings and Valuation

This table compares Lantheus and Heska's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$347.34 million3.67$31.67 million$1.1716.29
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60

Lantheus has higher revenue and earnings than Heska. Lantheus is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.0% of Lantheus shares are held by institutional investors. Comparatively, 96.1% of Heska shares are held by institutional investors. 2.1% of Lantheus shares are held by company insiders. Comparatively, 11.7% of Heska shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Lantheus and Heska, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lantheus01302.75
Heska01402.80

Lantheus currently has a consensus target price of $23.6667, indicating a potential upside of 24.17%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Lantheus' higher probable upside, equities research analysts clearly believe Lantheus is more favorable than Heska.

Summary

Lantheus beats Heska on 8 of the 14 factors compared between the two stocks.


Heska Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Quidel logo
QDEL
Quidel
2.4$151.30+2.2%$6.40 billion$534.89 million17.76Analyst Revision
Neogen logo
NEOG
Neogen
1.2$79.75+2.6%$4.25 billion$418.17 million69.96
Intellia Therapeutics logo
NTLA
Intellia Therapeutics
1.3$51.81+5.0%$3.51 billion$43.10 million-22.72Analyst Upgrade
Analyst Revision
Gap Down
Riot Blockchain logo
RIOT
Riot Blockchain
0.9$40.30+9.9%$2.72 billion$6.84 million-67.17Analyst Downgrade
Decrease in Short Interest
Gap Down
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.84+2.1%$2.09 billion$638.60 million-10.71Analyst Report
Decrease in Short Interest
Gap Down
Lantheus logo
LNTH
Lantheus
1.7$19.06+3.0%$1.28 billion$347.34 million238.28Analyst Downgrade
Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$26.21+3.9%$1.04 billion$3.57 million-11.75News Coverage
Gap Up
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$21.91+3.8%$945.31 million$253.67 million20.29Analyst Report
Gap Up
Aspira Women's Health logo
AWH
Aspira Women's Health
1.5$6.72+1.2%$702.80 million$4.54 million-44.77
Oxford Immunotec Global logo
OXFD
Oxford Immunotec Global
1.1$21.99+0.0%$570.90 million$73.71 million-32.82Upcoming Earnings
News Coverage
Quotient logo
QTNT
Quotient
1.6$3.79+3.2%$383.29 million$32.66 million-3.21Gap Down
Nymox Pharmaceutical logo
NYMX
Nymox Pharmaceutical
0.7$2.43+2.5%$187.62 million$120,000.00-13.50Gap Down
Trinity Biotech logo
TRIB
Trinity Biotech
0.5$4.16+7.5%$86.95 million$90.43 million-7.17News Coverage
Gap Down
ICCC
ImmuCell
1.3$9.08+3.0%$65.49 million$13.72 million-39.48Gap Down
Biomerica logo
BMRA
Biomerica
1.3$5.50+6.2%$64.79 million$6.69 million-13.75Gap Down
ABIO
ARCA biopharma
0.9$4.12+3.4%$38.40 millionN/A-1.60Upcoming Earnings
Increase in Short Interest
Gap Up
Achieve Life Sciences logo
ACHV
Achieve Life Sciences
1.5$10.59+1.4%$38.32 millionN/A-0.96Upcoming Earnings
News Coverage
AKER
Akers Biosciences
0.7$2.75+4.0%$24.37 million$1.58 million0.00Increase in Short Interest
Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.